DIGIANDOMENICO ANTHONY 4

What Happened

• Anthony Digiandomenico, a director of ENDRA Life Sciences, was granted 60,324 restricted stock units (RSUs) on January 21, 2026. The Form 4 records the acquisition at $0.00 per share (typical for compensation awards) and lists total reported acquisition value as $0.

Key Details

• Transaction date: January 21, 2026; Form 4 filed: January 23, 2026 (appears to be timely).
• Security: 60,324 RSUs, reported as acquired under transaction code "A" (award/grant).
• Price: $0.00 per share as recorded on the filing (compensation grant, not an open-market purchase).
• Shares owned after transaction: not specified in this filing.
• Footnotes: F1 — RSUs convert to common stock 1:1; F1 notes the RSUs vest in full on January 21, 2027. F2 — includes unvested RSUs.
• No indication of a 10b5-1 plan, tax withholding sale, or immediate sale in this filing.

Context

• RSUs are a form of equity compensation that convert into shares if and when they vest; these units are unvested until Jan 21, 2027 and thus are not immediately tradable. Such grants reflect compensation/retention practices and should not be read as an immediate market buy or sell signal.